Used in cancer immunotherapy to block the TIGIT receptor on immune cells, enhancing anti-tumor immune responses. It works by preventing TIGIT from suppressing T cell and natural killer (NK) cell activity, allowing the immune system to better recognize and attack tumor cells. Often studied in combination with other checkpoint inhibitors like anti-PD-1/PD-L1 antibodies to improve treatment outcomes in solid tumors such as melanoma, non-small cell lung cancer, and others. Supports immune-mediated tumor cell killing and is used as a reference standard in preclinical and clinical research for developing new TIGIT-targeting therapies.